A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke

Clinical Rehabilitation

Volumn 26, Issue 9, 2012, Pages 787-797

  Dunne, John Walter ^a,b   Gracies, Jean Michel ^b   Hayes, Michael ^c   Zeman, Brian ^d   Singer, Barbara Jennifer ^a,e  

^a ROYAL PERTH HOSPITAL   (Australia)

^b HENRI MONDOR HOSPITAL   (France)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d ROYAL REHABILITATION CENTRE SYDNEY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Botulinum toxin; plantarflexor; randomized controlled trial; spasticity; stroke

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INJECTION; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE HYPERTONIA; NEUROLOGIC DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AUSTRALIA; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MUSCLE HYPERTONIA; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 84864858336     PISSN: 02692155     EISSN: 14770873     Source Type: Journal    
DOI: 10.1177/0269215511432016     Document Type: Article

References (33)

1. Paul SL, Srikanth VK, Thrift AG. The large and growing burden of stroke. Curr Drug Targets. 2007 ; 8: 786-793 (Pubitemid 47163388)
2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009 ; 8: 355-369
3. Stolov WC. The concept of normal muscle tone, hypotonia and hypertonia. Arch Phys Med Rehabil. 1966 ; 47: 156-156
4. Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005 ; 31: 535-551
5. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 ; 31: 552-571
6. Brainin M, Norrving B, Sunnerhagen KS, et al. International PSS Disability Study Group. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications. Int J Stroke. 2011 ; 6: 42-46
7. Simpson DM, Gracies JM, Graham HK, et al. Botulinum neurotoxin for the treatment of spasticity [an evidence-based review]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 ; 70: 1691-1698 (Pubitemid 351644137)
8. Elia AE, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord. 2009 ; 24: 801-812
9. Esquenazi A, Mayer NH, Elia AE, Albanese A. Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon. 2009 ; 54: 634-638
10. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009 ; 41: 13-25
11. Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb disorders of movement and muscle tone in adults: evidence-based guidelines. Eur J Neurol. 2010 ;: 57-73
12. Gracies JM, Singer BJ, Dunne JW. The role of botulinum toxin injections in the management of muscle overactivity of the lower limb. Disabil Rehabil. 2007 ; 29: 1789-1805
13. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010 ; 2: 74-93
14. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010 ; 257: 1330-1337
15. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry. 2000 ; 69: 499-506
16. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005 ; 26: 26-31 (Pubitemid 40723938)
17. Bayram S, Sivrioglu K, Karli N, Ozcan O. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil. 2006 ; 85: 75-81 (Pubitemid 43004858)
18. Farina S, Migliorini C, Gandolfi M, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol. 2008 ; 23: 87-91
19. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009 ; 90: 9-16
20. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995 ; 58: 232-235
21. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner. 1964 ; 192: 540-542
22. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol. 1990 ; 28: 512-515 (Pubitemid 20359157)
23. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 ; 94: 149-158 (Pubitemid 33016608)
24. Rothstein JM, Miller PJ, Roettger RF. Goniometric reliability in a clinical setting. Elbow and knee measurements. Phys Ther. 1983 ; 63: 1611-1615 (Pubitemid 13010970)
25. Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993 ; 13: 489-495 (Pubitemid 23174659)
26. Singer B, Dunne J, Allison G. Reflex and non-reflex elements of hypertonia in triceps surae muscles following acquired brain injury: implications for rehabilitation. Disabil Rehabil. 2001 ; 23: 749-757 (Pubitemid 33115100)
27. Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil. 2009 ; 23: 651-658
28. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil. 1999 ; 13: 373-383 (Pubitemid 29425632)
29. Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil. 2005 ; 27: 7-18 (Pubitemid 40124835)
30. Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. Clin Rehabil. 2006 ; 20: 173-182
31. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med. 2006 ; 38: 166-171 (Pubitemid 43731149)
32. Price CI, Curless RH, Rodgers H. Can stroke patients use visual analogue scales?. Stroke. 1999 ; 30: 1357-1361 (Pubitemid 29296061)
33. Turner-Stokes L, Williams H, Johnson J. Goal attainment scaling: does it provide added value as a person-centred measure for evaluation of outcome in neurorehabilitation following acquired brain injury?. J Rehabil Med. 2009 ; 41: 528-535